XNCR Xencor Inc
FY2025 10-K
Xencor Inc (XNCR) filed its fiscal year 2025 10-K annual report with the SEC on Feb 25, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Clinical-stage biopharma developing engineered XmAb antibody therapeutics targeting cancer and autoimmune diseases with modular bispecific Fc domain technology
- • New product emphasis: XmAb412, a bispecific antibody targeting TL1A and IL23p19 in autoimmune diseases, first-in-human studies planned for 2026
Management Discussion & Analysis
- • Revenue $125.6M in 2025, up $15.1M YoY from $110.5M in 2024, driven by Alexion and Incyte license agreements
- • Operating loss $177.5M in 2025, nearly flat vs $178.4M in 2024, representing an operating margin of -141.3% vs -161.4%
Risk Factors
- • Regulatory risk from FDA approvals with no products yet approved using XmAb platform, uncertain commercial viability of candidates
- • Geopolitical/macro risk from California concentration; wildfires or earthquakes could disrupt operations and third-party supply continuity
Get deeper insights on Xencor Inc
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.